Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans

F. Gerard Moeller, James M. Bjork, Donald M. Dougherty, Louis D. Van De Kar, Dawn M. Marsh, Alan C. Swann

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The 5-HT1B/D agonist sumatriptan has been used in a number of studies as a neuroendocrine challenge agent. Whether its neuroendocrine effects are centrally mediated is unclear, however, since sumatriptan shows minimal penetration of the central nervous system. Zolmitriptan shows a greater penetration into the central nervous system than sumatriptan, and has recently been shown to be an effective challenge agent. In order to determine the neuroendocrine, temperature and side effects of a 2.5 mg oral dose of zolmitriptan, 17 healthy volunteers underwent a placebo controlled, repeated measures, double blind neuroendocrine challenge. Zolmitriptan or placebo were administered, and cortisol, growth hormone, prolactin, blood pressure and temperature, were measured over four hours after the dose of zolmitriptan. Zolmitriptan at this dose was well tolerated by all subjects, with minimal side effects and only minor effects on blood pressure. There was a significant increase in serum growth hormone after zolmitriptan compared to placebo, however there were no significant effects on cortisol, prolactin or oral temperature. The neuroendocrine effects of 2.5 mg of orally administered zolmitriptan are similar to previously reported effects of sumatriptan, with minimal side effects. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)607-618
Number of pages12
Issue number6
StatePublished - Aug 2000
Externally publishedYes


  • Cortisol
  • Growth hormone
  • Neuroendocrine challenge
  • Prolactin
  • Serotonin
  • Zolmitriptan

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans'. Together they form a unique fingerprint.

Cite this